7,166 Shares in Axon Enterprise, Inc $AXON Purchased by NewEdge Wealth LLC

NewEdge Wealth LLC purchased a new stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) in the second quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 7,166 shares of the biotechnology company’s stock, valued at approximately $4,017,000.

Several other hedge funds have also bought and sold shares of AXON. Rockefeller Capital Management L.P. increased its stake in Axon Enterprise by 53.2% during the 4th quarter. Rockefeller Capital Management L.P. now owns 11,518 shares of the biotechnology company’s stock valued at $6,542,000 after purchasing an additional 4,002 shares in the last quarter. Legal & General Group Plc lifted its stake in shares of Axon Enterprise by 1.3% in the fourth quarter. Legal & General Group Plc now owns 426,533 shares of the biotechnology company’s stock worth $242,241,000 after buying an additional 5,419 shares in the last quarter. Eurizon Capital SGR S.p.A. bought a new position in shares of Axon Enterprise in the fourth quarter worth approximately $13,116,000. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Axon Enterprise during the first quarter valued at approximately $15,067,000. Finally, Harel Insurance Investments & Financial Services Ltd. grew its holdings in shares of Axon Enterprise by 40.7% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 15,083 shares of the biotechnology company’s stock valued at $6,406,000 after buying an additional 4,360 shares during the last quarter. Institutional investors own 79.08% of the company’s stock.

Insider Buying and Selling

In other Axon Enterprise news, President Joshua Isner sold 13,000 shares of the stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $488.45, for a total value of $6,349,850.00. Following the transaction, the president owned 169,125 shares of the company’s stock, valued at approximately $82,609,106.25. This represents a 7.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Elizabeth Reid Coughlin sold 1,554 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $485.00, for a total value of $753,690.00. Following the completion of the transaction, the insider directly owned 34,024 shares in the company, valued at $16,501,640. The trade was a 4.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 68,989 shares of company stock valued at $36,016,932 over the last ninety days. 4.20% of the stock is owned by insiders.

Axon Enterprise Trading Up 4.2%

Shares of AXON stock opened at $645.72 on Thursday. The company has a current ratio of 2.15, a quick ratio of 1.80 and a debt-to-equity ratio of 0.47. Axon Enterprise, Inc has a 12-month low of $339.01 and a 12-month high of $794.29. The stock has a market capitalization of $52.46 billion, a P/E ratio of 267.93, a P/E/G ratio of 10.06 and a beta of 1.39. The firm’s 50 day moving average is $536.03 and its 200 day moving average is $474.89.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Tuesday, August 4th. The biotechnology company reported $1.88 earnings per share for the quarter, beating analysts’ consensus estimates of $1.84 by $0.04. The business had revenue of $904.39 million during the quarter, compared to analyst estimates of $876.42 million. Axon Enterprise had a net margin of 6.19% and a return on equity of 2.84%. The company’s quarterly revenue was up 35.3% compared to the same quarter last year. During the same period in the previous year, the business earned $2.12 EPS. Research analysts expect that Axon Enterprise, Inc will post 2.04 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on AXON shares. UBS Group upped their price objective on Axon Enterprise from $440.00 to $600.00 and gave the company a “neutral” rating in a research report on Thursday, August 6th. The Goldman Sachs Group reissued a “buy” rating and issued a $715.00 target price on shares of Axon Enterprise in a report on Thursday, August 6th. Piper Sandler boosted their price target on Axon Enterprise from $724.00 to $732.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Morgan Stanley upped their price target on Axon Enterprise from $600.00 to $640.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Finally, Barclays increased their price objective on Axon Enterprise from $523.00 to $688.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Thirteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $730.92.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.